Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

According to Dr. Daniel Koller, Head Investment Management Team BB Biotech, at Bellevue Asset Management, resilience is evident amidst the current uncertainty in biotech. In this Q&A Koller explains to us why he believes that the biotech sector will emerge stronger in 2024.

Resilience amidst uncertainty in biotech: A Q&A with BB Biotech’s Dr Daniel Koller

According to Dr. Daniel Koller, Head Investment Management Team BB Biotech, at Bellevue Asset Management, resilience is evident amidst the current uncertainty in biotech. In this Q&A Koller explains to us why he believes that the biotech sector will emerge stronger in 2024.
08.03.2024 - Daniel Koller